Kezar Life Sciences (NASDAQ:KZR) Trading 4.7% Higher

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZRGet Rating) traded up 4.7% on Thursday . The company traded as high as $8.45 and last traded at $8.30. 146,309 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 1,442,297 shares. The stock had previously closed at $7.93.

A number of analysts recently issued reports on the company. Wells Fargo & Company raised their price target on Kezar Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday. Jonestrading raised their price target on Kezar Life Sciences from $17.00 to $20.00 in a research report on Tuesday. Finally, HC Wainwright raised their price target on Kezar Life Sciences from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, March 18th.

The company has a market capitalization of $561.26 million, a P/E ratio of -8.93 and a beta of 0.54. The business has a 50-day moving average of $6.68 and a 200-day moving average of $11.90. The company has a debt-to-equity ratio of 0.04, a current ratio of 35.25 and a quick ratio of 35.25.

Kezar Life Sciences (NASDAQ:KZRGet Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.03. Sell-side analysts predict that Kezar Life Sciences, Inc. will post -1.19 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in KZR. Dorsey Wright & Associates bought a new stake in shares of Kezar Life Sciences during the first quarter worth $60,000. Amalgamated Bank bought a new stake in shares of Kezar Life Sciences during the first quarter worth $70,000. Metropolitan Life Insurance Co NY bought a new stake in shares of Kezar Life Sciences during the third quarter worth $85,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Kezar Life Sciences in the fourth quarter valued at about $93,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Kezar Life Sciences in the first quarter valued at about $167,000. Institutional investors and hedge funds own 71.03% of the company’s stock.

Kezar Life Sciences Company Profile (NASDAQ:KZR)

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.

Read More

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.